Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLBS Caladrius Biosciences		$6.37	$0.38 ▼ $1.24	$26.05M	0.91	522,308 shs	466,373 shs
COYA Coya Therapeutics	$6.86 +4.1%	$6.03	$4.65 ▼ $10.24	$114.73M	0.26	52,070 shs	94,743 shs
HLVX HilleVax	$2.06 -0.5%	$2.04	$1.34 ▼ $2.17	$103.29M	0.77	965,910 shs	480,165 shs
PRE Prenetics Global	$7.25 -0.5%	$8.02	$3.09 ▼ $11.99	$94.14M	0.15	32,320 shs	147,656 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLBS Caladrius Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
COYA Coya Therapeutics	0.00%	+11.54%	+2.08%	+16.27%	+15.29%
HLVX HilleVax	0.00%	-0.96%	-3.74%	+10.75%	+3.00%
PRE Prenetics Global	0.00%	-4.61%	-10.05%	-29.68%	+25.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	1.8633 of 5 stars	3.5	2.0	0.0	0.0	2.5	0.8	0.0
HLVX HilleVax	1.1562 of 5 stars	1.0	4.0	0.0	0.0	0.0	3.3	1.3
PRE Prenetics Global	1.7187 of 5 stars	2.5	4.0	0.0	0.0	1.3	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLBS Caladrius Biosciences	0.00	N/A	N/A	N/A
COYA Coya Therapeutics	3.00	Buy	$16.50	140.52% Upside
HLVX HilleVax	2.00	Hold	$2.00	-2.91% Downside
PRE Prenetics Global	3.00	Buy	$9.00	24.14% Upside

Current Analyst Ratings Breakdown

Latest CLBS, PRE, HLVX, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/8/2025	HLVX HilleVax	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
COYA Coya Therapeutics	$423.45K	270.95	N/A	N/A	$1.69 per share	4.06
HLVX HilleVax	N/A	N/A	N/A	N/A	$2.95 per share	N/A
PRE Prenetics Global	$30.62M	3.07	N/A	N/A	$13.20 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLBS Caladrius Biosciences	-$27.47M	-$0.41	N/A	N/A	N/A	N/A	-27.24%	-26.08%	N/A
COYA Coya Therapeutics	-$14.88M	-$1.24	N/A	N/A	N/A	N/A	-61.05%	-53.61%	11/5/2025 (Estimated)
HLVX HilleVax	-$147.27M	-$1.43	N/A	N/A	N/A	N/A	-34.29%	-28.50%	11/6/2025 (Estimated)
PRE Prenetics Global	-$46.30M	-$3.99	N/A	N/A	N/A	-115.91%	-28.07%	-22.27%	10/6/2025 (Estimated)

Latest CLBS, PRE, HLVX, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	-$0.36	-$0.14	-$0.36	$0.78 million	$0.16 million
8/6/2025	Q2 2025	HLVX HilleVax	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A
6/12/2025	Q1 2025	PRE Prenetics Global	N/A	-$0.80	N/A	-$0.80	N/A	$17.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
PRE Prenetics Global	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLBS Caladrius Biosciences	N/A	22.33	22.33
COYA Coya Therapeutics	N/A	7.43	7.43
HLVX HilleVax	N/A	26.39	26.39
PRE Prenetics Global	N/A	2.07	1.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLBS Caladrius Biosciences	15.57%
COYA Coya Therapeutics	39.75%
HLVX HilleVax	86.42%
PRE Prenetics Global	25.01%

Insider Ownership

Company	Insider Ownership
CLBS Caladrius Biosciences	2.20%
COYA Coya Therapeutics	12.00%
HLVX HilleVax	24.90%
PRE Prenetics Global	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLBS Caladrius Biosciences	27	60.58 million	59.25 million	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
PRE Prenetics Global	1	12.98 million	11.97 million	Not Optionable

CLBS, PRE, HLVX, and COYA Headlines

Recent News About These Companies

Prenetics Global Divests ACT Genomics Stake and Invests in Bitcoin

August 22 at 8:50 AM | tipranks.com

Prenetics Global (NASDAQ:PRE) Trading Up 1.8% - Should You Buy?

August 21 at 3:04 AM | marketbeat.com

Prenetics Approves Major Share Capital Increase at August 2025 Meeting

August 1, 2025 | tipranks.com

Prenetics Global (NASDAQ:PRE) Shares Up 0.5% - Here's Why

July 29, 2025 | marketbeat.com

Prenetics Global Limited (PRE) Earnings Surprise Summary (EPS ...

July 25, 2025 | seekingalpha.com

Prenetics Global Limited Adopts Bitcoin Treasury Strategy Amidst Market Volatility

July 17, 2025 | tipranks.com

PRE Prenetics Global Limited - Seeking Alpha

July 9, 2025 | seekingalpha.com

Prenetics Global Limited (PRE) - Yahoo Finance

June 30, 2025 | finance.yahoo.com

Aryna Sabalenka Adds Her Muscle to IM8 as Ambassador & Shareholder

June 30, 2025 | msn.com

Aryna Sabalenka Becomes First Current Athlete Shareholder in Prenetics' IM8 Supplements Brand

June 26, 2025 | quiverquant.comQ

World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

June 26, 2025 | globenewswire.com

Cardone Capital goes all-in on Bitcoin adding 1K BTC to its reserve

June 23, 2025 | msn.com

$1.24 Billion in Bitcoin Added to Corporate Treasuries This Week

June 22, 2025 | coingape.comC

A South Korean Biotech Firms Gets $183.3M Funding to Build Bitcoin Treasury

June 21, 2025 | coindesk.com

Healthcare Meets Crypto: David Beckham–Backed Prenetics Launches $20M Bitcoin Treasury

June 20, 2025 | techstory.inT

Prenetics Global (NASDAQ:PRE) Stock, Short Interest Report

June 19, 2025 | benzinga.com

Prenetics Adopts $20M Bitcoin Treasury Strategy

June 19, 2025 | thecurrencyanalytics.comT

Prenetics Global First Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line

June 19, 2025 | finance.yahoo.com

Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

June 18, 2025 | globenewswire.com

Prenetics Global Limited Divests ACT Genomics, Strengthens Financial Position and Raises FY2025 Revenue Outlook

June 18, 2025 | quiverquant.comQ

Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction

June 18, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLBS, PRE, HLVX, and COYA Company Descriptions

Caladrius Biosciences NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Coya Therapeutics NASDAQ:COYA

$6.86 +0.27 (+4.10%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.82 -0.04 (-0.58%)

As of 08/22/2025 07:52 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

HilleVax NASDAQ:HLVX

$2.06 -0.01 (-0.48%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.06 +0.00 (+0.24%)

As of 08/22/2025 07:17 PM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Prenetics Global NASDAQ:PRE

$7.25 -0.04 (-0.55%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$7.24 0.00 (-0.07%)

As of 08/22/2025 04:10 PM Eastern

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time